Furthermore, in a heterotopic xenograft model, gemcitabine exposure activates NF-κB within established pancreatic tumors, suggesting that NF-κB suppression may also improve the anti-tumor effects of gemcitabine in vivo[21]. This evidence concerns the gene NFKB1 and pancreatic neoplasm.